Drug
Shr A2102
Shr A2102: highest development phase Phase 2/3, developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| SHR-A2102 NCT06879145 | Phase 2/3 | Muscular Invasive Bladder Cancer (MIBC) |
Latest
No recent events.
Follow Shr A2102 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.